Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 725 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia, Mild Clear all
Completed Early Phase 1 Interventional

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Alzheimer Disease
Interventions
Nicotinamide riboside
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

NCT02221622
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

NCT02423200
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VX-745
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

NCT05584241
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
Interventions
Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Not applicable Interventional

The "Let's Talk Tech" Tool to Support Decision Making About Technology Use

NCT06817122
View directory record Official record
Conditions
Dementia, Mild, Mild Cognitive Impairment (MCI)
Interventions
Let's Talk Tech
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Risk Evaluation and Education for Alzheimer's Disease

NCT00571025
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
APOE Disclosure
Behavioral
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 28, 2026, 5:41 AM EDT
Recruiting Phase 2 Interventional

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Interventions
natural product combination-1 (NPC1)
Combination Product
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Not listed No phase listed Observational

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT06400368
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
NeuroVision Imaging
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 28, 2026, 5:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 28, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 28, 2026, 5:41 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Software Validation Study-Cognitive Status Indicator

NCT06809725
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
SPARK Cognitive Status Indicator (software support data collected via EEG)
Diagnostic Test
Lead sponsor
Spark Neuro Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 28, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional

Choose Myself (Before) Losing Myself

NCT07846566
View directory record Official record
Conditions
Dementia (Diagnosis), Mild Cognitive Impairment, Alzheimer's Disease Dementia, Alzheimer's Disease
Interventions
CYOA booklet
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Mid-frontal Delta/Theta and Cognitive Control

NCT06984757
View directory record Official record
Conditions
Parkinson&Amp;Amp;#39;s Disease (PD)
Interventions
Deep-brain Stimulation, Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
Device
Lead sponsor
Nandakumar Narayanan
Other
Eligibility
18 Years to 99 Years
Enrollment
635 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
AR1001, Placebo
Drug
Lead sponsor
AriBio Co., Ltd.
Industry
Eligibility
55 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Banning, California • Sacramento, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 28, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3954068, Placebo, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 28, 2026, 5:41 AM EDT
Not listed Phase 2 Interventional

Phase II Clinical Trial of Interleukin-2 in AD

NCT06096090
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interleukin-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 28, 2026, 5:41 AM EDT
Enrolling by invitation No phase listed Observational

Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals

NCT06017505
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
Interventions
electronic self administered gerocognitive examination (eSAGE)
Diagnostic Test
Lead sponsor
Douglas Scharre
Other
Eligibility
50 Years and older
Enrollment
1,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 5:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

NCT05107882
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Las Vegas, Nevada • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 28, 2026, 5:41 AM EDT
Not listed Phase 2 Interventional

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

NCT00174525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-001
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
50 Years to 85 Years
Timeline
2005 – 2008
U.S. locations
2
States / cities
Los Alamitos, California • Northridge, California
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 28, 2026, 5:41 AM EDT
Not listed Not applicable Interventional

Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease

NCT04606420
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lifestyle medicine
Behavioral
Lead sponsor
Preventive Medicine Research Institute
Other
Eligibility
45 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
San Diego, California • Sausalito, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotine Treatment of Cognitive Decline in Down Syndrome

NCT01778946
View directory record Official record
Conditions
Down Syndrome, Mild Cognitive Impairment
Interventions
Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 28, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Metformin in Amnestic Mild Cognitive Impairment

NCT00620191
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 28, 2026, 5:41 AM EDT